Teva Pharmaceutical Industries Ltd (NYSE:TEVA) CAO Deborah A. Griffin sold 2,376 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $7.83, for a total value of $18,604.08. Following the transaction, the chief accounting officer now owns 2,376 shares of the company’s stock, valued at approximately $18,604.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Teva Pharmaceutical Industries stock opened at $7.45 on Monday. The company has a debt-to-equity ratio of 1.73, a current ratio of 0.96 and a quick ratio of 0.62. Teva Pharmaceutical Industries Ltd has a one year low of $6.07 and a one year high of $24.96. The stock has a market capitalization of $8.22 billion, a PE ratio of 2.66, a price-to-earnings-growth ratio of 0.79 and a beta of 1.68. The business’s fifty day moving average is $7.22 and its 200 day moving average is $10.88.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 16.04% and a negative net margin of 21.94%. The company had revenue of $4.34 billion for the quarter, compared to analysts’ expectations of $4.25 billion. During the same period last year, the firm posted $0.78 earnings per share. Teva Pharmaceutical Industries’s revenue was down 7.7% compared to the same quarter last year. As a group, sell-side analysts expect that Teva Pharmaceutical Industries Ltd will post 2.25 EPS for the current fiscal year.
A number of research firms have recently commented on TEVA. Barclays began coverage on Teva Pharmaceutical Industries in a research note on Tuesday, June 11th. They issued an “underweight” rating and a $8.00 target price on the stock. Bank of America cut Teva Pharmaceutical Industries from a “buy” rating to an “underperform” rating and cut their target price for the stock from $19.00 to $9.00 in a research note on Thursday, May 30th. JPMorgan Chase & Co. cut their target price on Teva Pharmaceutical Industries from $9.00 to $7.00 and set an “underweight” rating on the stock in a research note on Friday, September 6th. UBS Group set a $8.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Friday, August 16th. Finally, Mizuho set a $11.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Monday, June 17th. Six investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $12.80.
Several institutional investors have recently added to or reduced their stakes in the stock. First Interstate Bank purchased a new position in Teva Pharmaceutical Industries in the second quarter worth about $28,000. Pacer Advisors Inc. purchased a new position in Teva Pharmaceutical Industries in the second quarter worth about $32,000. Kavar Capital Partners LLC purchased a new position in Teva Pharmaceutical Industries in the second quarter worth about $35,000. G&S Capital LLC boosted its position in Teva Pharmaceutical Industries by 99.4% in the second quarter. G&S Capital LLC now owns 4,012 shares of the company’s stock worth $37,000 after purchasing an additional 2,000 shares during the last quarter. Finally, NEXT Financial Group Inc boosted its position in Teva Pharmaceutical Industries by 384.8% in the second quarter. NEXT Financial Group Inc now owns 4,276 shares of the company’s stock worth $39,000 after purchasing an additional 3,394 shares during the last quarter. 57.85% of the stock is currently owned by institutional investors.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Read More: Understanding Options Trading
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.